Literature DB >> 31669825

Higher CD56+ or CD2+ lymphocyte percentage predicts poor steroid response in patients with immune thrombocytopenia.

Yi-Feng Wu1, Wei-Han Huang2, Ming-Huei Gu3, Siao-Ru Lin3, Sung-Chao Chu4, Tso-Fu Wang4, Chi-Cheng Li5.   

Abstract

INTRODUCTION: Immune thrombocytopenia (ITP) is known as an immune-mediated disease and often evolves to chronic type in adult. Corticosteroids only work in around 60% of patients. This study evaluated the roles of subgroup lymphocytes from peripheral blood in ITP adults with different treatment response.
METHODS: Between October 2009 and March 2017, 37 adults were newly diagnosed as ITP requiring treatment. The patients were separated into two groups: 23 patients with platelet count <50,000/μL with corticosteroid dependence or second-line treatment (Poor-responder Group), and 14 patients with platelet counts <50,000/μL with standard steroid treatment, which stopped within three months (Good-responder Group). Subgroup lymphocyte percentages of peripheral blood were determined through flow cytometry before treatment. Data analysis with Mann-Whitney test and receiver operating characteristic curves were performed using GraphPad Prism (Version 7). A p-value of <0.05 was considered significant.
RESULTS: Lymphocyte percentage was significantly lower in Poor-responder Group than in Good-responder Group (p = 0.008). In subgroup lymphocytes, higher percentages of CD19+ B lymphocytes were found in Good-responder Group (p = 0.03). In Poor-responder Group, a higher CD2+ and CD56+ lymphocytes were observed (p = 0.02 and 0.03). By the cut-off value of percentage of CD56+ lymphocytes with 24.5% or CD2+ lymphocytes with 85.7%, the specificity showed 92.86%.
CONCLUSIONS: This study found that newly diagnosed ITP patients with increased percentages of CD56+ or CD2+ lymphocytes in peripheral blood associated with a poorer response to steroid treatment.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Flow cytometry; Immune thrombocytopenia; Lymphocyte subgroup; Steroid response

Mesh:

Substances:

Year:  2019        PMID: 31669825     DOI: 10.1016/j.thromres.2019.10.011

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  1 in total

1.  Entecavir-associated thrombocytopenia.

Authors:  Yi Yu; Hao Feng
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.